Allink Biotherapeutics
PrivateLast Round
Series A
Extension
Dec 16, 2025
Total Funding Raised
$112.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Allink Biotherapeutics operates in Healthcare & Life Sciences and is based in Shanghai. Its latest recorded funding round was a Series A Extension round in December 2025.
Allink Biotherapeutics is a biotechnology company that develops a pipeline of First-in-Class and Best-in-Class antibody-drug conjugates and multispecific antibody therapeutics for oncology and immunology diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Allink Biotherapeutics Comparables
Compare Allink Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| MediLink Therapeutics | 85% | |
| Valink Therapeutics | 83% | |
| Sidewinder Therapeutics | 82% |
For institutional investors. Book with your work email.
Allink Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Dec 16, 2025 | ||||
| Series A | Nov 28, 2024 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Allink Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lanchi Ventures | Series A Extension, Series A |
| YuanBio Venture Capital | Series A Extension, Series A |
| Lapam Capital | Series A Extension |
| Legend Capital | Series A, Series A Extension |
| 5Y Capital | Series A Extension |
| C&D Emerging Industry Equity Investment | Series A |
| Medfine Capital | Series A, Angel |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 42% MoM, reaching 1.4K.
- Dec 16, 2025
$47M raised in Series A Extension round.
For institutional investors. Book with your work email.
Allink Biotherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Allink Biotherapeutics's valuation, stock price, and market status.
Is Allink Biotherapeutics a public or private company?
Allink Biotherapeutics is a private company.
What is the current stock price of Allink Biotherapeutics?
Allink Biotherapeutics is a private company, so its shares have no public market price. Caplight tracks Allink Biotherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Allink Biotherapeutics worth (valuation)?
Valuation information for Allink Biotherapeutics is not publicly available.
Can I buy Allink Biotherapeutics stock?
Allink Biotherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Allink Biotherapeutics's last funding round?
Allink Biotherapeutics's most recent funding round was Series A Extension on December 16, 2025.
Who are the main investors in Allink Biotherapeutics?
Key investors in Allink Biotherapeutics include Lanchi Ventures, Legend Capital, Medfine Capital, Lanchi Ventures, Meituan Long-Z Investment.
Will Allink Biotherapeutics IPO soon?
No public IPO plans have been announced for Allink Biotherapeutics.
How can I track Allink Biotherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Allink Biotherapeutics's shares on secondary markets.